GenSci161 Injection Clinical Trial Application of Changchun High-Tech Subsidiary Accepted by Regulator

Stock News

Aug 31

Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance Notice issued by the National Medical Products Administration, confirming that the domestic drug registration clinical trial application for the GenSci161 injection has been formally accepted.

Developed independently by Jinsai Pharmaceutical, the GenSci161 injection is a Class 1 therapeutic biological product intended for the treatment of connective tissue disease-associated interstitial lung disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1113021196"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113021196\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113021196?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113021196","market":"sh","top_or_hot":-1,"title":"GenSci161 Injection Clinical Trial Application of Changchun High-Tech Subsidiary Accepted by Regulator","media":"Stock News","content":"<p><b>Changchun High-Tech Industry (Group) Co., Ltd.</b> (<b>000661.SZ</b>) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance Notice issued by the National Medical Products Administration, confirming that the domestic drug registration clinical trial application for the GenSci161 injection has been formally accepted.<br><br>Developed independently by Jinsai Pharmaceutical, the GenSci161 injection is a Class 1 therapeutic biological product intended for the treatment of connective tissue disease-associated interstitial lung disease.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GenSci161 Injection Clinical Trial Application of Changchun High-Tech Subsidiary Accepted by Regulator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenSci161 Injection Clinical Trial Application of Changchun High-Tech Subsidiary Accepted by Regulator\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-31 20:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Changchun High-Tech Industry (Group) Co., Ltd.</b> (<b>000661.SZ</b>) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance Notice issued by the National Medical Products Administration, confirming that the domestic drug registration clinical trial application for the GenSci161 injection has been formally accepted.<br><br>Developed independently by Jinsai Pharmaceutical, the GenSci161 injection is a Class 1 therapeutic biological product intended for the treatment of connective tissue disease-associated interstitial lung disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDTX","symbol_name":"Corgi MediaTek 2x Daily ETF","start_time":0,"source_url":"","article_id":"1113021196","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113021196","pubTimestamp":1788179298,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDTX":"Corgi MediaTek 2x Daily ETF","BK0046":"生物疫苗","BMED":"iShares Health Innovation Active ETF","BK0028":"国家队","BK0057":"长吉图板块","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK0239":"医药制造","BK0075":"新三板","000661":"长春高新","BK0188":"融资融券","IBBQ":"Invesco Nasdaq Biotechnology ETF","PSYK":"PSYK ETF"},"translate_title":"长春高新子公司GenSci161注射液临床试验申请获监管机构受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDTX":1,"BMED":1,"PSYK":1,"000661":1,"IBBJ":1,"IBBQ":1},"content_text":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance Notice issued by the National Medical Products Administration, confirming that the domestic drug registration clinical trial application for the GenSci161 injection has been formally accepted.Developed independently by Jinsai Pharmaceutical, the GenSci161 injection is a Class 1 therapeutic biological product intended for the treatment of connective tissue disease-associated interstitial lung disease.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}